These results suggested that ITGBL1 might serve as a novel prognostic biomarker for HCC patients, and the ITGBL1/TGF‐β1/Smads signalling pathways could act as potential targets for metastasis prevention in HCC patients. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.